ArticleInternational journal of pharmaceutics: X2026
GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma.
Zuo Mou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.